



## ICAV Fact Sheet

ICAV is a not-for-profit drug development organization dedicated to the discovery and development of anti-viral therapies for neglected and emerging diseases. ICAV's goal is to deliver one drug to market every five years that is affordable, effective, and accessible to all patients in need.

### Why ICAV is Needed

- Over 5 million people die each year from viral diseases.
- 2 billion people lack access to essential medicines.
- 15% of the world's population consumes over 90% of the world's pharmaceuticals
- Only 1% of new drugs were developed for neglected diseases over the last 30 years.
- A first line of defence against emerging pandemics, anti-virals provide crucial protection while a vaccine is developed, e.g., highly pathogenic avian influenza.
- Anti-viral drugs provide effective treatment for diseases for which there are no vaccines, such as HIV/AIDS.
- Commercial approaches to drug development have failed to yield an adequate pipeline of anti-viral drugs.

### How ICAV Works

ICAV is currently investigating over 20 lead compounds for development.

- ICAV accelerates the development of new therapeutics by taking promising compounds from academia through the drug development pipeline.
- ICAV gathers lead compounds from a scientific network of over 200 experts from 90 institutions in 24 countries.
- ICAV uses a Technical Review Committee, composed of industry experts, to evaluate and design development pathways for ICAV compounds.

### Cheaper Drugs

ICAV estimates that it can produce drugs at less than 20% of the cost of traditional pharmaceutical approaches.

- ICAV leverages billions of dollars spent each year by national governments on basic research.
- ICAV licences compounds after initial proof-of-concept, reducing risk of failure by 10.
- Public and philanthropic funding of pre-clinical development further reduces risk.
- Use of international scientific network throughout drug development pathway reduces personnel and infrastructure costs.

### Scientific Strategy

ICAV's scientific strategy focuses on developing wide-spectrum anti-virals—potentially effective against multiple viral diseases. By targeting cellular host and transmission functions, which are shared by many viruses, drugs will not only be effective against multiple diseases, such as hepatitis and HIV, but also potentially resistant to viral mutation.

### Intellectual Property

Where there are commercial opportunities, ICAV will partner with pharmaceutical companies while retaining rights for developing world markets in order to provide ICAV developed therapies in those regions at cost or for free.